How Analysts Feel About Casi Pharmaceuticals Incorporated (NASDAQ:CASI) After Increase in Sellers?

September 17, 2017 - By Vivian Park

 How Analysts Feel About Casi Pharmaceuticals Incorporated (NASDAQ:CASI) After Increase in Sellers?

Investors sentiment decreased to 0.88 in Q4 2016. Its down 0.25, from 1.13 in 2016Q3. It dropped, as 3 investors sold CASI Pharmaceuticals Inc shares while 5 reduced holdings. 1 funds opened positions while 6 raised stakes. 2.22 million shares or 0.50% more from 2.21 million shares in 2016Q3 were reported.
Blackrock Inv Mgmt Ltd Liability Corp owns 3,375 shares. Renaissance Technologies Lc holds 0% or 124,800 shares in its portfolio. Bank & Trust Of America Corporation De owns 1,144 shares or 0% of their US portfolio. Creative Planning reported 0% in CASI Pharmaceuticals Inc (NASDAQ:CASI). Wellington Shields Management Limited Company has invested 0.1% in CASI Pharmaceuticals Inc (NASDAQ:CASI). 19,589 are held by Royal State Bank Of Canada. Morgan Stanley holds 0% or 679 shares. Next Fincl Group accumulated 2 shares. Wells Fargo Mn stated it has 0% in CASI Pharmaceuticals Inc (NASDAQ:CASI). Geode Cap Llc holds 0% or 38,700 shares in its portfolio. Vanguard Group Inc Inc stated it has 0% of its portfolio in CASI Pharmaceuticals Inc (NASDAQ:CASI). Raymond James Finance Svcs Incorporated accumulated 55,090 shares or 0% of the stock. Wellington Shields & holds 505,474 shares. Moors Cabot holds 0.02% or 79,486 shares. Penobscot Inv Management reported 27,000 shares stake.

The stock of Casi Pharmaceuticals Incorporated (NASDAQ:CASI) registered an increase of 5.09% in short interest. CASI’s total short interest was 74,300 shares in September as published by FINRA. Its up 5.09% from 70,700 shares, reported previously. With 9,200 shares average volume, it will take short sellers 8 days to cover their CASI’s short positions. The short interest to Casi Pharmaceuticals Incorporated’s float is 0.2%.

The stock increased 15.38% or $0.2 on September 15, reaching $1.5. About 355,943 shares traded or 704.23% up from the average. CASI Pharmaceuticals Inc (NASDAQ:CASI) has declined 17.65% since September 17, 2016 and is downtrending. It has underperformed by 34.35% the S&P500.

CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The company has market cap of $90.29 million. The Firm is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It currently has negative earnings. It operates through the development of targeted therapeutics for the treatment of cancer segment.

CASI Pharmaceuticals Inc (NASDAQ:CASI) Ratings Coverage

Among 2 analysts covering CASI Pharmaceuticals Inc (NASDAQ:CASI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. CASI Pharmaceuticals Inc had 4 analyst reports since October 29, 2015 according to SRatingsIntel. The company was initiated on Thursday, October 29 by H.C. Wainwright. Maxim Group initiated it with “Buy” rating and $4 target in Thursday, September 22 report. The rating was maintained by Maxim Group on Monday, August 14 with “Buy”.

More notable recent CASI Pharmaceuticals Inc (NASDAQ:CASI) news were published by: Prnewswire.com which released: “CASI Pharmaceuticals To Present At The Annual Rodman & Renshaw Global …” on September 06, 2017, also Prnewswire.com with their article: “CASI Pharmaceuticals Reports First Quarter 2017 Financial Results” published on May 15, 2017, Prnewswire.com published: “CASI Pharmaceuticals Provides Update On Phase 2 Trial Of ENMD-2076 In …” on August 16, 2016. More interesting news about CASI Pharmaceuticals Inc (NASDAQ:CASI) were released by: Prnewswire.com and their article: “CASI Pharmaceuticals Reports 2015 Fourth Quarter And Full Year Financial Results” published on March 28, 2016 as well as Prnewswire.com‘s news article titled: “James E. Goldschmidt, Ph.D. Joins CASI Pharmaceuticals As Vice President Of …” with publication date: April 18, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.